Partial
Mostly Aligned
Patient Risk:
Low
Summary
The AI claims include several label-supported statements (antidepressant status; not approved for insomnia; key warnings), but numerous asserted claims are not supported by the label, resulting in partial alignment.
Category Scores
Accurate Statements
Trazodone is an antidepressant.
Indication/General pharmacology
Trazodone is not FDA-approved for insomnia.
Indication: no insomnia indication
Orthostatic hypotension occurs, especially in older adults.
Warnings and Precautions
Priapism is rare (<1%) and requires emergency care.
Warnings and Precautions
Not recommended in pregnancy (Category C).
Use in Pregnancy (Pregnancy Category C)
Not recommended for children under 18.
Pediatric Use
Discontinuation/Withdrawal: No abrupt stop needed at low doses—taper over 1-2 weeks to avoid rebound insomnia or anxiety.
7. Discontinuation/Withdrawal
Avoid with MAOIs.
Contraindications
Unsupported Statements
Trazodone causes sedation through histamine and alpha-1 receptor blockade.
Not present in label
Its main serotonin reuptake inhibition occurs at higher antidepressant doses.
Not present in label
Studies show trazodone reduces sleep latency by 10-30 minutes in people with primary insomnia or depression-related sleep issues.
Not present in label
Studies show trazodone increases total sleep time by 30-60 minutes in people with primary insomnia or depression-related sleep issues.
Not present in label
Response rates are around 60-80% in short-term trials (2-4 weeks).
Not present in label
Trazodone outperforms placebo in meta-analyses.
Not present in label
It shows similar efficacy to zolpidem for sleep maintenance.
Not present in label
It shows similar efficacy to doxepin for sleep maintenance.
Not present in label
It has lower abuse potential due to no GABA effects.
Not present in label
Benzodiazepines like lorazepam provide faster relief but have higher dependence risk.
Not present in label
Trazodone is preferred for long-term use in depression patients.
Not present in label
Trazodone mechanism for sleep is H1/5-HT2A blockade.
Not present in label
Typical dose for sleep is 25-100 mg.
Not present in label
Trazodone dependence risk is low.
Not present in label
Trazodone next-day impairment is moderate.
Not present in label
Drowsiness occurs in 24%.
Not present in label
Dry mouth occurs in 15%.
Not present in label
Dizziness occurs in 10%.
Not present in label
Orthostatic hypotension occurs, especially in older adults.
Already labeled as accurate; included above
Generic pricing: $4-10/month (GoodRx average).
Not present in label
Contradictions
Important Omissions
Dosing guidance for sleep onset vs maintenance and typical doses are not comprehensively documented in the label snippet provided.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Label-supported warnings (e.g., orthostatic hypotension, priapism) present but no high-risk, unaddressed safety signals identified from the evaluated claims.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Many non-label claims present; improve alignment by restricting statements to label-supported information and clearly separating approved indications, dosing, and safety.
Suggested Improvement
Limit claims to FDA-approved labeling; remove or flag non-label efficacy claims; provide dosing and administration details only if supported by label; include boxed warnings and explicit contraindications as per label.